[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urothelial-carcinoma-ureter-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urothelial-carcinoma-ureter-recurrent":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100506479","utract-jelmyto-registry-a-registry-of-patients-with-upper-tract-urothelial-cancer-utuc-treated-with-jelmyto-100506479",false,"NCT05874921","uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT","Inclusion Criteria:\n\n* Adults \\>18 years old and capable of giving informed consent.\n* Diagnosis of UTUC.\n* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).\n\nExclusion Criteria:\n\n* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).\n* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).\n* Pregnancy or lactation.\n* Unable to comply with protocol requirements (for prospective data capture).\n* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.",[26,27,28,29,30,31,32,33],"Urothelial Carcinoma","Urothelial Carcinoma Recurrent","Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma of the Renal Pelvis and Ureter","Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60],"Upper Tract Urothelial Cancer","UTUC","UGN-101","Mitomycin C","TCC","Ureteral","Upper Tract","Carcinoma","Kidney","Renal","Gel","Local","Prolonged Release","Slow Release","Kidney Sparing","Recurrence","Neoplasms by Histologic Type","Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Neoplasms by Site","Antibiotics, Antineoplastic","Antineoplastic Agents","Alkylating Agents","Nucleic Acid Synthesis Inhibitors","Enzyme Inhibitors","RECRUITING","2025-02-25",{"date":64,"type":65},"2025-02-28","ACTUAL",{"date":67,"type":65},"2023-11-17",{"date":69,"type":21},"2028-01",{"name":71,"class":72},"UroGen Pharma Ltd.","INDUSTRY",22,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":4,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":88,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":89,"locationsCount":4},"100477242","named-patient-program-for-mitomycin-for-pyelocalyceal-solution-100477242","NCT05494411","Named Patient Program for Mitomycin for Pyelocalyceal Solution","Inclusion Criteria:\n\n* Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.","EXPANDED_ACCESS","This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.",[30,31,28,29,26,27],[84,85,37,86],"Low-grade Upper Tract Urothelial Cancer","LG-UTUC","Mitomycin","AVAILABLE",{"date":64,"type":65},{"name":71,"class":72}]